HCA 10-Q Quarterly Reports

HCA Healthcare, Inc. (HCA) reported a strong third quarter of 2025, with revenues increasing by 9.6% to $19.161 billion and net income attributable to HCA Healthcare, Inc. rising by 29.4% to $1.643 billion, or $6.96 per diluted share. This robust performance was driven by a combination of increased patient volumes and higher revenue per equivalent admission. The company has also seen significant improvements in operational efficiencies, particularly in managing labor costs. Despite positive operational results, HCA highlighted several significant policy and economic uncertainties that could impact future performance. These include potential reductions in Medicare reimbursement due to the "One Big Beautiful Bill Act" (OBBBA), the expiration of enhanced premium tax credits (EPTCs) at the end of 2025, ongoing federal government shutdowns, and continued inflationary pressures on operating expenses. HCA is actively engaged in advocacy and implementing resiliency plans to mitigate these potential headwinds. Investors should monitor the evolving regulatory landscape and the company's ability to adapt to these changes.

HCA Healthcare, Inc. reported a strong second quarter for 2025, with consolidated revenues increasing by 6.4% year-over-year to $18.605 billion. This growth was driven by a 3.9% increase in revenue per equivalent admission and a 2.3% rise in equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a significant jump of 13.1% to $1.653 billion, translating to $6.83 per diluted share, up from $5.53 in the prior year's second quarter. This performance was bolstered by a substantial $2.239 billion increase in cash from operating activities, largely due to favorable working capital changes and a notable decline in income taxes paid thanks to a state tax deferral. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders. Despite the positive financial performance, the company faces evolving regulatory landscapes. The recently enacted One Big Beautiful Bill Act (OBBBA) introduces significant changes to Medicaid, potentially impacting patient access and federal health care spending. Additionally, changes to health insurance marketplace rules and the expiration of enhanced premium tax credits could affect payer mix. HCA Healthcare is actively monitoring these developments and implementing resiliency plans. The company's substantial debt load remains a factor, though management believes existing liquidity and access to capital markets are sufficient to meet future needs. Overall, HCA Healthcare delivered robust operational and financial results in the second quarter, while proactively addressing potential regulatory headwinds.

HCA Healthcare, Inc. reported solid financial performance for the first quarter of 2025, with revenues increasing by 5.7% year-over-year to $18.321 billion. This growth was driven by a combination of increased equivalent admissions and higher revenue per equivalent admission. Net income attributable to HCA Healthcare, Inc. reached $1.610 billion, or $6.45 per diluted share. While revenue and net income showed positive growth, the company experienced a significant decline in cash flow from operating activities, down $818 million to $1.651 billion, primarily due to negative changes in working capital. The company continues to execute its capital allocation strategy, with substantial share repurchases in the quarter. Management expressed confidence in its ability to meet liquidity needs through operating cash flows, available credit facilities, and access to debt markets, despite a significant debt load of $44.576 billion at the end of the quarter. The report also highlights ongoing risk factors, including inflationary pressures, regulatory changes in healthcare, and the management of substantial indebtedness.

HCA Healthcare, Inc. reported a strong third quarter of 2024, with revenues increasing by 7.9% to $17.487 billion and net income attributable to HCA Healthcare, Inc. rising by 17.7% to $1.270 billion ($4.88 per diluted share). This growth was driven by a combination of increased patient volumes, with equivalent admissions up 5.0%, and higher revenue per equivalent admission, up 2.8%. The company also saw a significant improvement in operating cash flow, which increased by $1.036 billion to $3.515 billion for the quarter, primarily due to favorable changes in working capital. Despite facing headwinds such as inflationary pressures on supplies and other operating expenses, and incurring approximately $50 million in losses and additional expenses related to Hurricane Helene, HCA Healthcare demonstrated resilience. The company has proactively managed labor costs, with a notable 17.8% decline in contract labor costs year-over-year. Looking ahead, HCA Healthcare anticipates further impacts from hurricanes Milton and Helene in the fourth quarter, estimated between $200 million and $300 million, but continues its strategic capital allocation through significant share repurchases and dividend payments, signaling confidence in its financial position.

HCA Healthcare, Inc. (HCA) reported strong financial results for the second quarter of 2024, showcasing significant year-over-year growth in both revenue and net income. Total revenues reached $17.492 billion, a 10.3% increase compared to the same period last year, driven by a healthy rise in revenue per equivalent admission and overall equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a substantial increase to $1.461 billion, translating to $5.53 per diluted share, up from $1.193 billion or $4.29 per diluted share in Q2 2023. This performance was bolstered by increased patient volumes, with a notable rise in admissions and emergency department visits, while surgeries saw a slight decline. Despite the robust revenue and profit growth, the company experienced a decline in cash flow from operating activities, primarily due to negative changes in working capital and higher income tax payments. However, HCA Healthcare maintained a strategic approach to capital allocation, repurchasing a significant amount of its common stock and continuing its dividend program. The company also highlighted its ongoing investments in capital expenditures, projecting between $5.1 billion and $5.3 billion for 2024, underscoring its commitment to facility improvements and expansion. Management expressed confidence in its ability to meet future liquidity needs through operating cash flows, credit facilities, and access to debt markets, while acknowledging persistent inflationary pressures on operating expenses.

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2024, with revenues increasing by 11.2% year-over-year to $17.339 billion. This growth was driven by a 7.1% increase in equivalent admissions and a 3.9% rise in revenue per equivalent admission, indicating robust patient volume and effective pricing strategies. Net income attributable to HCA Healthcare, Inc. rose by 16.7% to $1.591 billion, or $5.93 per diluted share, demonstrating improved profitability. The company also reported a significant increase in cash flow from operations, which grew by $666 million to $2.469 billion, primarily due to favorable working capital changes and higher net income. Despite significant planned capital expenditures of $5.1 billion to $5.3 billion for 2024, HCA Healthcare maintains a solid liquidity position, with substantial amounts available under its senior secured credit facilities. The company continued its commitment to shareholder returns through active share repurchases and dividend payments.

HCA Healthcare, Inc. (HCA) reported strong revenue growth in its third quarter of 2023, with total revenues reaching $16.213 billion, an increase of 8.3% year-over-year. This growth was driven by a combination of increased revenue per equivalent admission (up 3.6%) and higher equivalent admissions (up 4.5%). While revenue demonstrated robust performance, net income attributable to HCA Healthcare, Inc. saw a slight decrease to $1.079 billion ($3.91 per diluted share) from $1.134 billion ($3.91 per diluted share) in the prior year's quarter. This was partially influenced by a $105 million pre-tax loss related to a recently acquired hospital-based physician staffing joint venture. The company experienced an increase in patient volumes across key areas, with consolidated admissions up 2.8% and same-facility admissions up 3.4%. Emergency department visits and surgeries also saw modest increases. Despite the revenue growth, operating cash flow declined by $541 million to $2.479 billion, primarily due to unfavorable changes in working capital. Management anticipates continued inflationary pressures impacting operating expenses and maintains sufficient liquidity through operating cash flows, credit facilities, and access to debt markets.

HCA Healthcare, Inc. reported a solid second quarter for 2023, with revenues increasing by 7.0% to $15.861 billion compared to the same period in 2022. Net income attributable to HCA Healthcare, Inc. also saw a modest increase, reaching $1.193 billion, or $4.29 per diluted share. This growth was driven by a combination of increased patient volumes, evidenced by a 4.0% rise in equivalent admissions, and a 2.9% increase in revenue per equivalent admission. The company continues to manage its cost structure effectively, with salaries and benefits remaining relatively stable as a percentage of revenue, though other operating expenses, particularly professional fees, saw an increase. Cash flows from operations showed significant strength, increasing by $845 million year-over-year, largely due to positive changes in working capital. Despite economic uncertainties and inflationary pressures, HCA demonstrated resilience. The company experienced a decline in uninsured admissions, which is a positive sign for revenue collection. Management expects to fund significant capital expenditures, projected at $4.7 billion for 2023, through a combination of operational cash flow and debt. A notable event during the quarter was a data security incident announced in July 2023, involving patient information for approximately 11 million individuals. While the investigation is ongoing, HCA stated it does not believe this incident will materially impact its business or financial results.

HCA Healthcare, Inc. reported solid financial results for the first quarter of 2023, demonstrating revenue growth and improved profitability. Total revenues increased by 4.3% to $15.591 billion compared to the prior year, driven by a significant increase in equivalent admissions. Net income attributable to HCA Healthcare, Inc. also saw a healthy rise of 7.1% to $1.363 billion, resulting in earnings per diluted share of $4.85. The company's operational performance was characterized by a notable increase in patient volumes, with equivalent admissions up 6.7% and same-facility admissions rising by 4.4%. This growth was supported by a higher volume of surgeries and emergency department visits. While revenue per equivalent admission experienced a slight decline, this was largely attributed to the comparison with a prior year period that included higher COVID-19 volumes and reimbursement. From a financial health perspective, cash flow from operations significantly improved, increasing by $458 million to $1.803 billion, driven by both increased net income and favorable changes in working capital. Despite a robust increase in capital expenditures to support facility improvements and expansion, the company maintained its liquidity. HCA Healthcare also continued its commitment to shareholder returns through share repurchases and dividend declarations.

HCA Healthcare, Inc. reported revenues of $14.971 billion for the third quarter of 2022, a decrease of 2.0% compared to $15.276 billion in the third quarter of 2021. This revenue decline was primarily driven by a 3.2% decrease in revenue per equivalent admission, influenced by a significant reduction in COVID-19 patient volumes compared to the prior year. Net income attributable to HCA Healthcare, Inc. saw a substantial decrease to $1.134 billion ($3.91 per diluted share) from $2.269 billion ($7.00 per diluted share) in the prior year's third quarter. This decrease is largely due to the absence of a significant $1.047 billion gain on sales of facilities recorded in the third quarter of 2021, alongside increased operating expenses, particularly in 'other operating expenses' which rose to 19.1% of revenues from 16.6% due to higher costs for directed payment programs, professional fees, and utilities, along with increased provisions for professional liability risks. Despite the year-over-year decline in net income, operating cash flows increased by $743 million to $3.020 billion, driven by positive changes in working capital. The company also continued its share repurchase program and declared a quarterly dividend. Management anticipates that existing liquidity and access to capital markets will be sufficient to meet its needs for at least the next 12 months.

HCA Healthcare, Inc.'s (HCA) Q2 2022 filing shows a modest revenue increase of 2.7% to $14.82 billion, driven by a 4.2% rise in revenue per equivalent admission, despite a 1.5% decline in equivalent admissions. Net income attributable to HCA Healthcare, Inc. decreased by 20.3% to $1.155 billion, or $3.90 per diluted share, compared to $1.450 billion, or $4.36 per diluted share, in Q2 2021. This decline was impacted by losses on debt retirement and facility sales, as well as increased salaries and benefits, which rose as a percentage of revenue. The company continues to manage its significant debt load, which stood at $38.9 billion at the end of June 2022. Despite increased interest expenses, HCA maintains ample liquidity, with $2.725 billion available under its senior secured credit facilities. Management expressed confidence in their ability to meet liquidity needs through operating cash flows, credit facilities, and access to debt markets. The company also continued its share repurchase program, buying back $4.783 billion worth of stock in the first six months of 2022.

HCA Healthcare, Inc. reported a revenue increase of 6.9% to $14.945 billion for the first quarter of 2022, compared to $13.977 billion in the prior year period. This growth was driven by a combination of increased revenue per equivalent admission and higher equivalent admissions. However, net income attributable to HCA Healthcare, Inc. saw a decrease of 10.6% to $1.273 billion ($4.14 per diluted share) from $1.423 billion ($4.14 per diluted share) in the first quarter of 2021. The company experienced an increase in operating expenses, particularly in salaries and benefits, which rose as a percentage of revenue, and other operating expenses impacted by inflation. Despite the decline in net income, the company demonstrated robust activity in managing its capital structure. HCA Healthcare repurchased approximately $2.1 billion of its common stock in the quarter and issued $6 billion in senior secured notes. Cash flow from operations decreased significantly primarily due to changes in working capital, including a payment for deferred payroll taxes. Management believes existing liquidity and access to capital markets are sufficient to meet its needs over the next 12 months.

HCA Healthcare, Inc. (HCA) reported strong revenue growth for the third quarter of 2021, with a 14.8% increase to $15.276 billion compared to the prior year. This growth was driven by a combination of increased revenue per equivalent admission and a higher volume of equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a significant jump to $2.269 billion, or $7.00 per diluted share, a substantial increase from $668 million, or $1.95 per diluted share, in the third quarter of 2020. This surge in profitability was notably influenced by a $1.047 billion gain on sales of facilities in the current quarter, compared to a much smaller gain in the prior year. It is important to note that the prior year's third quarter results included a substantial $822 million reversal of government stimulus income. Excluding these one-time items, the underlying operational performance shows solid year-over-year improvement. The company experienced a rebound in patient volumes, with consolidated admissions up 5.9% and same-facility admissions up 6.8%. Emergency department visits showed particularly strong growth, increasing by 28.9% on a consolidated basis. However, inpatient surgery volumes were constrained, likely due to capacity being utilized to treat a surge in COVID-19 patients. The company continues to manage rising labor costs, with salaries and benefits as a percentage of revenue increasing slightly, and supply costs, particularly for pharmacy, also saw an increase driven by COVID-19 therapies and PPE utilization. Despite these cost pressures, HCA Healthcare demonstrated robust financial performance, supported by strategic facility sales and a general recovery in patient demand.

HCA Healthcare, Inc. reported strong financial results for the second quarter of 2021, with significant revenue and net income growth compared to the prior year. Revenues increased by 30.4% to $14.435 billion, driven by a robust rebound in patient volumes, including a 26.7% increase in equivalent admissions and a 37.7% rise in surgeries. Net income attributable to HCA Healthcare, Inc. surged by 34.3% to $1.450 billion, or $4.36 per diluted share. The company's operational recovery from the COVID-19 pandemic is evident in the substantial increase in patient volumes across various service lines, including emergency department visits and both inpatient and outpatient surgeries. While the company experienced a decline in cash flow from operating activities year-over-year, this was largely due to the absence of significant government stimulus income received in the prior year and changes in working capital. HCA Healthcare successfully refinanced a portion of its debt and has ample liquidity to meet its obligations.

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2021, with total revenues reaching $13.977 billion, an increase of 8.7% compared to the prior year. This revenue growth was driven by a significant 16.1% increase in revenue per equivalent admission, despite a 6.4% decline in equivalent admissions. This suggests a shift towards higher-acuity patients and favorable changes in payer mix, which offset lower patient volumes. Net income attributable to HCA Healthcare, Inc. saw a substantial jump to $1.423 billion, or $4.14 per diluted share, a significant increase from $581 million, or $1.69 per diluted share, in the first quarter of 2020. This robust profitability, coupled with strong operating cash flow of $1.988 billion, indicates effective cost management and operational efficiency in a recovering healthcare environment. The company also demonstrated a commitment to shareholder returns through substantial share repurchases and consistent dividend payments.

HCA Healthcare, Inc. (HCA) reported third-quarter 2020 results showing a revenue increase of 4.9% year-over-year to $13.311 billion, driven by a 15.3% increase in revenue per equivalent admission, despite a 9.1% decline in equivalent admissions. This performance indicates resilience and improved pricing power amidst the ongoing COVID-19 pandemic, which significantly impacted patient volumes, particularly elective procedures and emergency room visits. Net income attributable to HCA Healthcare, Inc. for the quarter was $668 million, or $1.95 per diluted share. This was impacted by a significant $822 million reversal of previously recognized government stimulus income related to the CARES Act Provider Relief Fund, which was recorded in the second quarter. Excluding this reversal, the company demonstrated strong operational performance. HCA also announced its decision to repay approximately $1.6 billion in Provider Relief Fund distributions and $4.4 billion in Medicare accelerated payments received under the CARES Act, which will be reflected in future cash flows.

HCA Healthcare, Inc. (HCA) reported its second-quarter 2020 results, a period significantly impacted by the COVID-19 pandemic. While consolidated revenues declined 12.2% year-over-year to $11.068 billion, net income attributable to HCA Healthcare, Inc. increased by 37.9% to $1.079 billion, or $3.16 per diluted share. This increase was largely driven by substantial government stimulus income received under the CARES Act, totaling $822 million ($590 million net of tax) in the quarter. Despite the revenue decline stemming from a significant drop in patient volumes, particularly elective procedures, the company's ability to increase revenue per equivalent admission by 9.7% partially offset the volume decrease. Operationally, HCA experienced a 20.0% decline in equivalent admissions, alongside a 26.5% decrease in surgeries and a 32.7% drop in emergency department visits. The company took proactive steps to enhance financial flexibility, including suspending share repurchases and dividends, and securing additional credit facilities. Cash flow from operations saw a substantial increase due to CARES Act funding and positive working capital changes. The company continues to monitor the evolving impact of the pandemic and has adjusted capital expenditures accordingly, while emphasizing its strong liquidity position to meet near-term obligations.

HCA Healthcare, Inc. (HCA) reported first quarter 2020 results that were impacted by the onset of the COVID-19 pandemic in the latter half of March. While consolidated revenues saw a modest increase of 2.7% year-over-year to $12.861 billion, driven by higher revenue per equivalent admission, net income attributable to HCA Healthcare, Inc. significantly decreased by 44.1% to $581 million, or $1.69 per diluted share. This decline was largely due to a substantial $295 million loss on the retirement of debt, alongside the initial impacts of the pandemic which led to a decline in elective procedures and patient volumes in the final weeks of the quarter. In response to the pandemic, HCA Healthcare took proactive steps to bolster financial flexibility. These included suspending its share repurchase program and quarterly dividend, reducing planned capital expenditures, and securing a new $2 billion term loan facility. The company also benefited from accelerated Medicare payments and Provider Relief Fund distributions under the CARES Act, receiving approximately $4.3 billion in accelerated Medicare payments and $900 million from the Provider Relief Fund in April 2020, which are crucial for maintaining liquidity amidst the uncertain operating environment. Despite these challenges and the significant impact of COVID-19, the company emphasized its belief that existing liquidity and access to capital markets would be sufficient to meet its needs over the next 12 months.

HCA Healthcare, Inc. reported a 10.9% increase in consolidated revenues for the third quarter of 2019, reaching $12.694 billion, up from $11.451 billion in the prior year's third quarter. This growth was driven by a 7.5% increase in equivalent admissions and a 3.1% rise in revenue per equivalent admission. However, net income attributable to HCA Healthcare, Inc. declined to $612 million ($1.76 per diluted share) from $759 million ($2.15 per diluted share) in the same period last year. This decrease was largely due to a significant $211 million loss on the retirement of debt in the current quarter, compared to a much smaller $9 million loss in the prior year. Despite the earnings dip, operational performance showed strength with increases in admissions, surgeries, and emergency department visits on both a consolidated and same-facility basis, indicating robust patient demand. For the first nine months of 2019, consolidated revenues grew by 9.9% to $37.813 billion, while net income attributable to HCA Healthcare, Inc. decreased to $2.434 billion ($6.98 per diluted share) from $2.723 billion ($7.65 per diluted share) in the comparable period of 2018. This decline was influenced by a large loss on debt retirement and lower gains on facility sales in the current year. The company continues to invest in its facilities, with capital expenditures (excluding acquisitions) increasing year-over-year, demonstrating a commitment to long-term growth and operational improvement. Management expresses confidence in the company's liquidity, citing sufficient cash flows from operations and available credit facilities.

HCA Healthcare, Inc. reported a solid performance for the second quarter of 2019, with revenues increasing by 9.3% to $12.602 billion compared to the prior year period. This growth was driven by a combination of increased patient volumes (6.2% rise in equivalent admissions) and a 3.0% increase in revenue per equivalent admission. While consolidated revenues showed strong growth, net income attributable to HCA Healthcare, Inc. saw a slight decrease to $783 million ($2.25 per diluted share) from $820 million ($2.31 per diluted share) in the second quarter of 2018. This decline in net income, despite revenue growth, can be attributed to increased operating expenses, particularly in salaries, benefits, and supplies, as well as higher interest expenses related to increased debt levels and a rise in depreciation and amortization. Operationally, the company experienced positive trends in admissions (up 4.8% consolidated, 2.1% same facility) and emergency department visits (up 4.9% consolidated, 3.0% same facility). Same-facility uninsured admissions also increased by 5.1%, highlighting continued demand from a diverse patient base. The company is actively managing its capital structure, issuing new debt and repurchasing shares, while also undertaking significant capital expenditures for facility improvements and expansions. Despite the increase in revenue, investors should note the slight dip in net income and the growing debt burden, which are key areas to monitor. The company also highlighted its strategic focus on expanding its network through acquisitions, notably a seven-hospital system in North Carolina. Cash flow from operations remained robust, increasing by $415 million year-over-year. Management expressed confidence in the company's liquidity and ability to meet its financial obligations for the next 12 months.

HCA Healthcare, Inc. (HCA) reported a solid first quarter for 2019, demonstrating revenue growth despite a year-over-year decrease in net income attributable to HCA Healthcare, Inc. Revenues increased by 9.6% to $12.517 billion, driven by an increase in both revenue per equivalent admission and equivalent admissions. However, net income attributable to HCA Healthcare, Inc. decreased to $1.039 billion ($2.97 per diluted share) from $1.144 billion ($3.18 per diluted share) in the prior year's first quarter. This decline was largely due to the absence of significant gains on sales of facilities that boosted the prior year's results, and a notable increase in cash used for investing activities, primarily driven by a significant acquisition. The company highlighted strong operational performance with increases in consolidated and same-facility admissions and surgeries. Investments in capital expenditures, including a substantial acquisition of a seven-hospital system in North Carolina, underscore HCA's commitment to growth and expanding its market presence. While cash flow from operations saw a decline, primarily due to working capital changes including a company 401(k) match payment, HCA maintains a strong liquidity position supported by available credit facilities and access to debt markets. The company continues to manage its significant debt load and focus on operational efficiencies.

HCA Healthcare, Inc. reported solid financial performance for the third quarter and the first nine months of 2018, demonstrating significant year-over-year growth in revenues and net income. Revenues increased by 7.1% in the third quarter and 7.3% for the nine-month period, driven by a combination of increased patient volumes (equivalent admissions) and higher revenue per equivalent admission. This growth, coupled with effective cost management, led to a substantial increase in profitability, with Net Income Attributable to HCA Healthcare, Inc. rising by 78.3% in the third quarter and 56.4% for the nine months compared to the prior year. The company benefited from a lower effective tax rate due to the Tax Cuts and Jobs Act of 2017, which significantly impacted reported net income. Additionally, operational improvements, including a reduction in the provision for professional liability risks and controlled labor and supply costs, further bolstered earnings. HCA Healthcare also continued its strategic capital allocation through share repurchases and strategic acquisitions, underscoring a commitment to enhancing shareholder value while managing its extensive network of healthcare facilities.

HCA Healthcare, Inc. (HCA) reported a strong second quarter and first half of 2018, demonstrating robust revenue growth and improved profitability. Revenues increased by 7.4% for the quarter and 7.5% for the six-month period, driven by a combination of higher patient volumes (equivalent admissions) and increased revenue per equivalent admission. Net income attributable to HCA Healthcare, Inc. saw a significant jump of 24.9% for the quarter and 49.3% for the six months, reflecting improved operational performance and the positive impact of tax reform. The company's operational metrics, such as admissions, surgeries, and emergency department visits, showed positive trends, indicating healthy demand for its services. Despite an increase in operating expenses, particularly salaries and benefits, HCA managed to improve its profit margins. The company also continued its capital allocation strategy through share repurchases and dividend payments, signaling confidence in its financial health and future prospects. The impact of the Tax Cuts and Jobs Act was a notable factor, contributing to lower effective tax rates and increased net income.

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2018, with revenues increasing by 7.5% year-over-year to $11.423 billion. Net income attributable to HCA Healthcare, Inc. saw a significant increase of 73.5% to $1.144 billion, or $3.18 per diluted share, compared to $659 million, or $1.74 per diluted share, in the prior year period. This robust growth was driven by a combination of increased patient volumes (equivalent admissions up 4.6%) and higher revenue per equivalent admission (up 2.9%). The company also benefited from a substantial one-time gain of $405 million from the sale of facilities and a lower effective tax rate due to the Tax Cuts and Jobs Act. Operationally, HCA demonstrated consistent volume growth across key metrics, including admissions and emergency department visits. The company also continued its strategic initiatives, including acquisitions and share repurchases, while managing its capital structure effectively. Despite facing ongoing healthcare industry challenges, HCA's performance indicates strong operational execution and favorable market dynamics in the reported quarter.

HCA Healthcare, Inc. (HCA) reported its third-quarter and nine-month results for the period ending September 30, 2017. For the third quarter, revenues increased by 4.2% year-over-year to $10.696 billion, while net income attributable to HCA Healthcare, Inc. decreased by 31.1% to $426 million, or $1.15 per diluted share, compared to $618 million, or $1.59 per diluted share, in the prior year period. This decline in net income was primarily influenced by approximately $140 million in expenses and lost revenue due to Hurricanes Harvey and Irma, and a $50 million negative impact from the Texas Medicaid Waiver program. For the first nine months of 2017, revenues grew by 3.9% to $32.052 billion. Net income attributable to HCA Healthcare, Inc. decreased by 11.6% to $1.742 billion, or $4.64 per diluted share, compared to $1.970 billion, or $4.93 per diluted share, in the same period last year. The company also continued its share repurchase program, buying back approximately $1.475 billion of stock in the first nine months of 2017. Despite the quarterly net income decline, operational metrics such as revenue per equivalent admission and equivalent admissions showed growth, indicating underlying demand for services.

HCA Healthcare, Inc. (HCA) reported solid financial results for the second quarter and first half of 2017. For the quarter ended June 30, 2017, revenues grew 4.0% year-over-year to $10.733 billion, while net income attributable to HCA remained stable at $657 million, translating to $1.75 in diluted earnings per share. This performance reflects steady growth in patient volumes and revenue per admission, demonstrating the company's operational resilience and ability to manage costs effectively. The company continues to execute its growth strategy through targeted acquisitions and capital investments, as evidenced by $1.304 billion in capital expenditures (excluding acquisitions) during the first half of 2017. HCA also maintained a strong liquidity position, with significant cash flows from operations and available credit facilities, supporting its ongoing financial commitments and strategic initiatives, including share repurchases.

HCA Healthcare, Inc. (HCA) reported revenues of $10.623 billion for the first quarter ended March 31, 2017, an increase of 3.5% from $10.260 billion in the prior year period. Despite the revenue growth, net income attributable to HCA Healthcare, Inc. decreased to $659 million ($1.74 per diluted share) from $694 million ($1.69 per diluted share) in the first quarter of 2016. This decrease was influenced by an increase in salaries and benefits, supplies, and other operating expenses as a percentage of revenue, and a higher provision for doubtful accounts. The company continues to manage a significant debt load, with total debt at $31.514 billion as of March 31, 2017. Operational metrics showed modest growth, with equivalent admissions increasing by 1.8% and revenue per equivalent admission rising by 1.7%. Same-facility revenues saw a 3.3% increase. The company actively engaged in share repurchases, spending $424 million in the quarter, and maintained ample liquidity with $2.139 billion available under its credit facilities.

HCA Healthcare, Inc. (HCA) reported solid financial performance for the third quarter and first nine months of 2016. Revenues saw a notable increase, driven by both higher patient volumes and improved revenue per equivalent admission. The company demonstrated strong operational efficiency, with growth across key metrics like admissions and outpatient surgeries. A significant positive development was the resolution of federal income tax issues for tax years 2011 and 2012, which resulted in a substantial tax benefit and boosted net income. The company also continued its strategic financial management, including significant share repurchases and debt refinancing activities aimed at optimizing its capital structure and reducing interest expense. While facing ongoing challenges such as healthcare reform and litigation, HCA's operational execution and financial discipline position it favorably. Investors should note the company's continued investment in capital expenditures and acquisitions as it expands its healthcare network and service offerings.

HCA Healthcare, Inc. reported strong financial performance for the second quarter and first six months of 2016, with revenues increasing by 4.3% and 5.1% respectively, compared to the prior year periods. Net income attributable to HCA Holdings, Inc. also saw significant growth, up 29.8% for the quarter and 23.1% for the six-month period, driven by increased patient volumes and revenue per equivalent admission. The company continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. While operational performance was robust, investors should note the ongoing legal proceedings, particularly the Health Midwest litigation, which resulted in a significant accrued liability. The company's substantial debt load remains a key consideration for financial health. Despite these factors, HCA Healthcare's financial results indicate a healthy operational performance and a positive outlook for the period.

HCA Healthcare, Inc. (HCA) reported its first quarter 2016 results, demonstrating solid revenue and net income growth. Total revenues increased by 6.0% to $10.26 billion compared to the prior year's first quarter, driven by a 2.2% increase in revenue per equivalent admission and a 3.7% rise in equivalent admissions. Net income attributable to HCA Holdings, Inc. saw a significant increase of 17.3% to $694 million, or $1.69 per diluted share, up from $591 million, or $1.36 per diluted share, in the first quarter of 2015. This growth was bolstered by operational improvements and a favorable tax benefit related to the early adoption of a new accounting standard. The company experienced increased patient volumes across various service lines, including admissions, outpatient surgeries, and emergency department visits, indicating strong demand for its services. Despite a notable increase in the provision for doubtful accounts and self-pay revenue deductions, which reflects the ongoing challenges in collectibility from uninsured patients, HCA managed to improve its profitability. The company also actively engaged in capital allocation, repurchasing approximately $621 million of its common stock during the quarter, underscoring management's confidence in its financial health and commitment to shareholder returns.

HCA Healthcare, Inc. (HCA) reported third quarter 2015 results showing revenue growth driven by increased patient volumes and slight price improvements. For the three months ended September 30, 2015, consolidated revenues increased by 6.9% to $9.856 billion compared to the prior year quarter, driven by a 4.8% increase in equivalent admissions. This growth was partially offset by a significant increase in the provision for doubtful accounts. Net income attributable to HCA Holdings, Inc. for the quarter was $449 million, or $1.05 per diluted share, down from $518 million, or $1.16 per diluted share, in the prior year quarter, largely due to $77 million in legal claim costs recognized in the current quarter. The nine-month period ended September 30, 2015, also showed revenue growth of 7.9% to $29.429 billion. Net income attributable to HCA Holdings, Inc. increased to $1.547 billion, or $3.60 per diluted share, compared to $1.348 billion, or $2.98 per diluted share, in the prior year. This improvement was despite significant expenses related to debt retirement and legal claims. The company continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

HCA Healthcare, Inc. reported strong financial performance for the second quarter and the first six months of 2015, demonstrating robust revenue growth and increased net income compared to the prior year. Revenues saw a significant increase of 7.2% year-over-year for the quarter, driven by a rise in equivalent admissions and revenue per equivalent admission. This top-line growth translated into improved profitability, with net income attributable to HCA Holdings, Inc. rising by 4.9% for the quarter and a substantial 32.3% for the six-month period. The company also continued its focus on capital allocation through significant share repurchases. While operating expenses, particularly salaries and benefits and supplies, increased, they were managed effectively relative to revenue growth. The company also highlighted its strong liquidity position, supported by operational cash flows and available credit facilities, enabling continued investment in capital expenditures. Despite facing ongoing challenges in the healthcare industry, including regulatory changes and the complexities of reimbursement, HCA Healthcare has shown resilience and a capacity for growth. Investors should note the company's strategic debt management, ongoing share repurchase programs, and commitment to operational efficiency as key indicators of its financial health and future prospects.

HCA Healthcare, Inc. reported strong first-quarter 2015 results, demonstrating significant top-line growth and improved profitability compared to the prior year. Total revenues increased by 9.5% year-over-year, driven by a combination of increased patient volumes and slight improvements in revenue per equivalent admission. This revenue growth translated into a substantial increase in net income, which more than doubled from the first quarter of 2014, largely due to operational efficiencies and a favorable swing in income tax benefits. The company's operational performance was robust, with solid growth in admissions, equivalent admissions, and surgical volumes across both consolidated and same-facility metrics. A notable trend highlighted is the significant decline in uninsured patient admissions and the corresponding reduction in the provision for doubtful accounts, which management attributes to increased health coverage through insurance exchanges and Medicaid expansion programs. This positive trend contributed to improved operating margins. Financially, HCA Healthcare managed its debt effectively, with a slight decrease in overall interest expense due to lower average interest rates, despite a notable increase in long-term debt due within one year. The company also continued its share repurchase program, returning capital to shareholders. Overall, the first quarter of 2015 signals a period of strong operational execution and financial recovery for HCA Healthcare.

HCA Holdings, Inc. (HCA) reported strong financial performance for the nine months ended September 30, 2014, with revenues increasing by 7.6% to $27.28 billion compared to the same period in the prior year. Net income attributable to HCA Holdings, Inc. also saw a significant increase of 19.1%, reaching $1.35 billion, with diluted earnings per share rising to $2.98 from $2.44 in the prior year. This growth was driven by a combination of increased patient volumes, higher revenue per equivalent admission, and a reduction in the provision for doubtful accounts, likely benefiting from broader healthcare coverage expansion. Operationally, HCA saw improvements across key metrics, including a 2.1% increase in consolidated admissions and a 3.3% rise in consolidated equivalent admissions for the nine-month period. The company also experienced a notable decrease in uninsured admissions, attributing this to increased coverage through health insurance exchanges and Medicaid expansion programs. Despite significant legal claims and ongoing government investigations, HCA's liquidity remains robust, supported by strong operating cash flows and available credit facilities, enabling continued investment in capital expenditures and share repurchases.

HCA Healthcare, Inc. (HCA) reported a strong second quarter for 2014, with revenues increasing by 9.2% year-over-year to $9.230 billion. This growth was driven by a 5.4% increase in revenue per equivalent admission and a 3.6% increase in equivalent admissions. Net income attributable to HCA Holdings, Inc. rose by 14.3% to $483 million, or $1.07 per diluted share. The company benefited from a significant increase in Medicaid revenues related to the Texas Medicaid Waiver Program and a reduction in the provision for doubtful accounts, attributed to more patients gaining coverage through health insurance exchanges and Medicaid expansion. Despite a substantial $226 million loss on debt retirement, the company demonstrated improved operational performance and solid revenue growth.

HCA Holdings, Inc. reported its first quarter 2014 financial results, showing a slight increase in net income attributable to HCA Holdings, Inc. to $347 million ($0.76 per diluted share) from $344 million ($0.74 per diluted share) in the prior year's quarter. Total revenues grew by 4.6% to $8.832 billion. The company experienced revenue growth driven by an increase in revenue per equivalent admission, despite a slight decrease in equivalent admissions. Operational highlights include a notable increase in the provision for doubtful accounts and associated uninsured discounts, indicating pressure from patients with less insurance coverage. The company also recorded significant legal claim costs related to the Health Midwest litigation. Financially, HCA managed its debt by issuing new notes and repaying existing ones, demonstrating active capital management. The company maintains a strong liquidity position with substantial credit facilities available. However, the company faces ongoing legal and regulatory scrutiny, including investigations into billing practices and a recent adverse ruling in the UK regarding competition in the private healthcare market, for which an appeal is planned. Investors should monitor the impact of healthcare reform, evolving reimbursement policies, and the resolution of ongoing legal matters.

HCA Healthcare, Inc. (HCA) reported financial results for the third quarter and first nine months of 2013. For the third quarter, revenues increased by 4.9% year-over-year to $8.456 billion, and net income attributable to HCA Holdings, Inc. was $365 million, or $0.79 per diluted share. This represents a slight increase from the prior year's third quarter net income of $360 million, or $0.78 per diluted share. For the first nine months of 2013, revenues grew by 3.1% to $25.346 billion, while net income attributable to HCA Holdings, Inc. declined to $1.132 billion, or $2.44 per diluted share, from $1.291 billion, or $2.81 per diluted share, in the same period of 2012. The company experienced growth in key volume metrics such as admissions and surgeries, alongside an increase in revenue per equivalent admission. However, the provision for doubtful accounts and self-pay revenue deductions saw a significant increase, impacting profitability. The company also noted a substantial decrease in electronic health record incentive income compared to the prior year. Despite these pressures, HCA Healthcare continues to invest in its facilities with capital expenditures and manages its substantial debt load.

HCA Healthcare, Inc. (HCA) reported solid revenue growth in the second quarter of 2013, with revenues increasing by 4.2% to $8.450 billion, driven by a 3.0% increase in revenue per equivalent admission and a 1.1% rise in equivalent admissions. Net income attributable to HCA Holdings, Inc. saw a notable increase of 8.1% to $423 million, translating to $0.91 per diluted share, up from $0.85 in the prior year's quarter. The company demonstrated operational improvements, with same-facility revenues growing by 4.0%. However, the six-month period presented a different picture, with net income attributable to HCA Holdings, Inc. declining by 17.7% to $767 million, or $1.66 per diluted share, compared to $931 million, or $2.03 per diluted share, in the same period of 2012. This decline was impacted by specific Medicare revenue adjustments in the prior year and the inclusion of debt retirement losses in the current period. Despite this, the company maintained a strong focus on managing its capital structure and liquidity, with significant operating cash flows and available credit facilities.

HCA Healthcare, Inc. reported its first quarter 2013 financial results, showing a slight increase in revenue to $8.44 billion, up from $8.405 billion in the prior year's first quarter. However, net income attributable to HCA Holdings, Inc. saw a significant decrease, falling to $344 million ($0.74 per diluted share) compared to $540 million ($1.18 per diluted share) in the first quarter of 2012. This decline was influenced by several factors, including a loss on debt retirement and sale of facilities in the current quarter, and beneficial Medicare revenue adjustments in the prior year. Operational metrics showed mixed results, with a slight increase in consolidated admissions but a decrease in both inpatient and outpatient surgeries. The company experienced an increase in its provision for doubtful accounts and uninsured discounts, reflecting challenges in patient collections. Despite the lower net income, the company's liquidity remains a focus, with substantial debt levels and ongoing capital expenditure plans. Investors should monitor the company's ability to manage its debt and navigate the evolving healthcare regulatory landscape.

HCA Holdings, Inc. reported a significant increase in net income attributable to HCA Holdings, Inc. for the nine months ended September 30, 2012, reaching $1.291 billion, a substantial rise from $530 million in the same period of the prior year. This growth was driven by an 11.1% increase in quarterly revenues to $8.062 billion and a 12.2% increase in nine-month revenues to $24.579 billion, benefiting from the consolidation of the HCA-HealthONE LLC venture and favorable Medicare adjustments. While revenue growth was robust, the company also saw an increase in the provision for doubtful accounts and uninsured discounts. The company's balance sheet reflects substantial long-term debt of $25.182 billion as of September 30, 2012, but it also demonstrates healthy operating cash flows, with $2.912 billion generated in the first nine months of 2012. The company also highlighted its ongoing efforts in EHR adoption and has provided updated estimates for EHR incentive income and related expenses.

HCA Healthcare, Inc. (HCA) reported strong financial performance for the second quarter and first six months of 2012, demonstrating significant year-over-year growth in revenues and net income. Revenues increased by 11.9% in the second quarter and 12.7% for the six-month period, driven by higher patient volumes and revenue per equivalent admission. Net income attributable to HCA Holdings, Inc. saw a substantial increase of 70.3% in the second quarter and 98.4% for the first six months, reflecting improved operational efficiency and favorable revenue trends. The company's operating expenses also saw an increase, primarily in salaries, benefits, and supplies, in line with revenue growth. However, cost control measures appear to be effective, as the company managed to improve its profit margins. HCA also highlighted positive cash flow generation from operations, providing flexibility for investments and debt management. The company continues to invest in its facilities and appears well-positioned to navigate the evolving healthcare landscape, including the impact of healthcare reform.

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2012, with revenues increasing by 13.5% to $8.4 billion compared to the same period in 2011. This growth was driven by a 11.4% increase in equivalent admissions and a 1.9% rise in revenue per equivalent admission, partly bolstered by the full consolidation of the HCA-HealthONE LLC venture. Net income attributable to HCA Holdings, Inc. significantly improved, reaching $540 million ($1.18 per diluted share) from $240 million ($0.52 per diluted share) in the prior year. This improvement was aided by substantial Medicare revenue adjustments totaling $188 million, though partially offset by a retroactive reduction of $83 million. The company also benefited from a decrease in interest expense by $91 million due to a lower average effective interest rate on its debt. However, cash flows from operations saw a decline primarily due to changes in working capital. HCA Healthcare continues to manage its significant debt load and is actively engaged in capital allocation, including a $971 million distribution to stockholders declared in February 2012. The company maintains a positive outlook, anticipating continued revenue growth and managing operational costs, while also addressing ongoing legal and regulatory matters.

HCA Healthcare, Inc. (HCA) reported its financial results for the third quarter and the first nine months of 2011. The company experienced revenue growth, with Q3 revenues increasing by 5.5% year-over-year to $7.310 billion and nine-month revenues rising by 5.4% to $22.004 billion. This growth was driven by an increase in patient volumes (equivalent admissions) across both consolidated and same-facility operations, although revenue per equivalent admission saw a slight decline or modest increase. A significant factor impacting net income was a substantial loss on the retirement of debt in Q3 2011, amounting to $406 million. This, along with other charges like a $181 million termination fee for a management agreement in the first nine months of 2011, contributed to a significant year-over-year decrease in net income attributable to HCA Holdings, Inc., which fell to $61 million in Q3 2011 from $243 million in Q3 2010, and to $530 million for the nine months ended September 30, 2011, from $924 million in the prior year period. The company also completed a significant initial public offering (IPO) in March 2011 and a large share repurchase in September 2011, impacting share counts and capital structure.

This 10-Q filing for HCA Healthcare, Inc. (HCA) as of June 29, 2011, highlights significant operational and legal developments. The company's disclosure controls and procedures were deemed effective by its CEO and CFO, with no material changes to internal controls over financial reporting during the period. However, HCA faces ongoing legal and regulatory scrutiny, including a Department of Justice review concerning implantable cardio-defibrillator (ICD) billing across 95 of its hospitals. This review, spanning from October 2003 to the present, could potentially lead to claims under the False Claims Act, with the ultimate impact currently unpredictable. The filing also addresses material risk factors, particularly concerning government health care programs. HCA derives approximately 41% of its revenue from Medicare and Medicaid, making it susceptible to changes in reimbursement policies. The Budget Control Act of 2011 and the Health Reform Law introduce potential reductions in Medicare payments and program integrity initiatives. Furthermore, many states are facing budgetary pressures that could lead to reduced Medicaid reimbursements, as exemplified by an estimated $50 million reduction for HCA hospitals in Florida in late 2011 and early 2012. Changes in these governmental programs, along with commercial payer responses, could materially affect HCA's financial position and results of operations.

HCA Healthcare, Inc. (HCA) filed its quarterly report on May 10, 2011, for the period ending March 30, 2011. A significant event during this period was the company's initial public offering (IPO) on March 15, 2011, where it raised approximately $2.5 billion in net proceeds. These proceeds were initially used to temporarily repay outstanding indebtedness under revolving credit facilities. Investors should note that HCA operates in a highly regulated and litigious healthcare industry. The company is subject to various government investigations, including a review by the Department of Justice regarding billing for implantable cardio-defibrillators (ICDs) at 87 HCA hospitals. Furthermore, changes in government healthcare programs, such as Medicare and Medicaid, represent a significant risk factor, with approximately 41% of HCA's revenues derived from these programs in 2010. Proposed changes to Medicare reimbursement rates and state budget pressures affecting Medicaid reimbursements could adversely impact future revenues.

This Form 10-Q for the period ending September 29, 2010, provides an update on HCA Healthcare, Inc.'s (HCA) operational and legal status. A key point for investors is the company's ongoing engagement with legal and regulatory matters, a common characteristic of the healthcare industry. While HCA reported that its Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) expired in January 2009 and was formally accepted in April 2010, thereby relieving them of future obligations under that specific agreement, the potential for future government scrutiny or private 'qui tam' actions remains. Investors should note that the resolution of such legal proceedings, particularly those involving government investigations, could materially impact HCA's financial position, results of operations, and liquidity. Furthermore, the filing details an amended and restated joinder agreement for HCA's senior secured revolving credit facility, establishing a new credit series maturing in November 2015. The effectiveness of these new credit facilities is contingent upon the company receiving proceeds from an initial public offering (IPO) or a specified date in May 2012, with potential adjustments to credit margins based on leverage ratios. This indicates a potential path towards an IPO and the company's focus on its capital structure as it navigates the regulatory landscape.

This 10-Q filing for HCA Healthcare, Inc. (HCA) for the period ending June 29, 2010, primarily focuses on regulatory and legal matters rather than detailed financial performance. A key takeaway is the conclusion of an eight-year Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) in April 2010, which HCA views as a positive development, although the government could still review the adequacy of its past reporting. This marks a significant step in addressing past regulatory scrutiny. Investors should be aware of the inherent risks in operating within a highly regulated healthcare industry. HCA reiterates its commitment to complying with extensive federal and state laws and regulations, including those related to billing, physician relationships (Stark Law, Anti-kickback Statute), and data privacy. The company acknowledges that certain arrangements may not qualify for safe harbor protection, potentially inviting greater scrutiny. Additionally, HCA highlights the potential impact of failing to effectively implement electronic health record (EHR) systems, which could affect future Medicare reimbursement rates.

This 10-Q filing for HCA Healthcare, Inc. for the period ending March 30, 2010, highlights the company's operational landscape dominated by significant regulatory and competitive pressures. A key focus for investors is the ongoing impact of the recently enacted Health Reform Law, which introduces both potential opportunities through expanded insurance coverage and significant risks related to Medicare and Medicaid reimbursement reductions. The company also faces intensified competition, increased patient financial responsibility, and ongoing government investigations and litigation. While management expresses confidence in its controls and procedures, the complexity and uncertainty surrounding the healthcare reform and its implications on revenue streams and operational costs warrant careful investor consideration.

This 10-Q filing for HCA Healthcare, Inc. as of September 29, 2009, focuses on market risk, controls, and legal proceedings. Management has affirmed the effectiveness of their disclosure controls and procedures, with no material changes to internal controls over financial reporting during the period. The company is involved in ongoing litigation, including a significant merger-related lawsuit in New Hampshire which is awaiting a court ruling, and a previously dismissed class action complaint regarding nurse understaffing. Investors should note that the company's operations are inherently subject to legal and regulatory challenges, which could materially impact financial results.

HCA Healthcare, Inc.'s (HCA) 10-Q filing for the period ending June 29, 2009, indicates a company operating within a complex regulatory and litigious environment. While the report highlights strong internal controls and no material changes in financial reporting procedures, it also flags significant risks related to healthcare reform and potential reductions in government program reimbursements. The company is actively managing its legal proceedings, with key litigation concerning merger-related disputes and a notable class-action lawsuit related to alleged nurse understaffing. Investors should note the substantial exposure to Medicare and Medicaid, which accounted for approximately 59% of admissions in 2008, and the potential impact of upcoming regulatory changes on revenue streams. The company also disclosed a minor issuance of common stock to employees and a modest share repurchase program during the quarter.